A new breed of high-cost diagnostics are entering a commercial and regulatory environment that isn't designed for them. Can they prosper?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pray, L.A. Molecular Diagnostics: New Growth, New Markets (Cambridge Healthtech Advisors, Waltham, MA, 2005).
Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
van de Vijver, M. et al. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baker, M. New-wave diagnostics. Nat Biotechnol 24, 931–938 (2006). https://doi.org/10.1038/nbt0806-931
Issue Date:
DOI: https://doi.org/10.1038/nbt0806-931
This article is cited by
-
Biomarker patents for diagnostics: problem or solution?
Nature Biotechnology (2012)